Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180689 | 0.88 | L3MBTL1 (0.61) | L3MBTL1NAMPTGAACA1CA2 | |
| SCHEMBL20019864 | 0.85 | CA1 (0.49) | TRPV1L3MBTL1GAACA1CA2 | |
| SCHEMBL1585947 | 0.85 | CA2 (0.53) | TRPV1NAMPTCA1CA2MAPT | |
| SCHEMBL6609140 | 0.83 | TSHR (0.56) | TRPV1 | |
| Boric Acid SCHEMBL27878882 | 0.83 | HPGD (0.55) | L3MBTL1NAMPTGAACA1CA2 | |
| SCHEMBL3519181 | 0.83 | HDAC1 (0.56) | TRPV1L3MBTL1NAMPTGAAHDAC1 | |
| SCHEMBL1162968 | 0.82 | GLS (0.49) | L3MBTL1NAMPTCA1HDAC1 | |
| SCHEMBL1164796 | 0.82 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAACA1CA2 | |
| SCHEMBL5796279 | 0.82 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAACA1CA2 | |
| SCHEMBL15259134 | 0.82 | L3MBTL1 (0.56) | L3MBTL1NAMPTGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112707924-A | Synthetic method of 4-aminomethyl phenylboronic acid hydrochloride | 蚌埠中实化学技术有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-9938410-B2 | Rhodamine dyes and conjugates | PHARMACOPHOTONICS, INC. (US) | 2018-04-10 | — | — | US | claimed |
| US-20160208101-A1 | NOVEL RHODAMINE DYES AND CONJUGATES | PHARMACOPHOTONICS, INC. D/B/A FAST DIAGNOSTICS | 2016-07-21 | — | — | US | claimed |
| EP-3802500-B1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4650001-A2 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Neurosterix Pharma Sàrl (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| EP-4337664-B1 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMACEUTICALS SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060128741-A1 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-20060106062-A1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2006053166-A1 | 8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | TRPV1 4569/4885L3MBTL1 4680/4885NAMPT 2821/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | TRPV1 1158/4885L3MBTL1 4829/4885NAMPT 451/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | TRPV1 3927/4885L3MBTL1 3922/4885NAMPT 235/4885 |
| US-20060106062-A1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | TRPV1 4447/4885L3MBTL1 4260/4885NAMPT 4357/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | TRPV1 4586/4885L3MBTL1 1047/4885NAMPT 2881/4885 |
| US-12479828-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | TRPV1 155/4885L3MBTL1 4237/4885NAMPT 446/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | TRPV1 911/4885L3MBTL1 2446/4885NAMPT 3420/4885 |
| US-20060128741-A1 | 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, CYP4B1 | TRPV1 126/4885L3MBTL1 4047/4885NAMPT 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.